Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Genotypic and phenotypic characterization was performed of HIV-1 isolates from treatment-naive HIV-1-infected patients experiencing virologic failure (VF) during treatment with the nonnucleoside reverse transcriptase inhibitor (NNRTIs) rilpivirine or efavirenz in the pooled phase 3 studies ECHO and THRIVE. Among 686 patients receiving rilpivirine, 72 (10%) experienced VF versus 39 of 682 (6%) receiving efavirenz. In patients with low baseline viral load (VL) ≤100,000 copies per milliliter, the proportions of rilpivirine VFs (19 of 368) and efavirenz VFs (16 of 330) were the same (5%). In patients with high baseline VL >100,000 copies per milliliter, the proportion of VFs was higher with rilpivirine (53 of 318; 17%) than efavirenz (23 of 352; 7%). The rate of rilpivirine VF was comparable between HIV-1 subtype B-infected (11%) and nonsubtype B-infected (8%) patients. The absolute number of VFs with treatment-emergent NNRTI resistance-associated mutations (RAMs) was higher for rilpivirine (most commonly E138K or K101E) than efavirenz (most commonly K103N), but relative proportions were similar [63% (39 of 62) vs. 54% (15 of 28), respectively]. More rilpivirine VFs had treatment-emergent nucleoside/nucleotide reverse transcriptase inhibitor RAMs than efavirenz VFs [68% (42 of 62) versus 32% (9 of 28), respectively], most commonly M184I and M184V. The proportion of rilpivirine VFs with RAMs in patients with low baseline VL was lower than in those with high baseline VL [38% (6 of 16) versus 72% (33 of 46) for NNRTI RAMs and 44% (7 of 16) versus 76% (35 of 46) for nucleoside/nucleotide reverse transcriptase inhibitor RAMs, respectively]. In summary, VF and treatment-emergent reverse transcriptase RAMs were similar at low baseline VL but more frequent at high baseline VL in rilpivirine-treated than in efavirenz-treated patients. The frequent emergence of E138K, especially in combination with M184I, in rilpivirine VFs is a unique finding of these trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
Bennett, D. E., Camacho, R. J., Otelea, D., Kuritzkes, D. R., Fleury, H., Kiuchi, M., Heneine, W., Kantor, R., Jordan, M. R., Schapiro, J. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004724 · Cited by 938
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625 · cited 4×
“K101E 2(13) 6 (13) 8 (13) V106M 0 3 (19) 3 (11)”
InfluentialMolina, J.-M., Cahn, P., Grinsztejn, B., Lazzarin, A., Mills, A., Saag, M., Supparatpinyo, K., Walmsley, S., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60936-7 · Cited by 405 · cited 7×
“2, respectively)(11); (2) K101E, E138K, E138G, Y181C, H221Y emerged in at least 3 RPV VFs—these RAMs were in the list of 39 excluded at baseline in ECHO and THRIVE(10); (3) E138R and E138Q were found to frequently emerge in in-vitro selection experiments in strains with decreased susceptibility to RPV(11); (4) E138A w…”
BackgroundInfluentialSelf-citationCohen, C. J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M. A., Ruxrungtham, K., Wu, H., Zorrilla, C., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60983-5 · Cited by 374
Self-citationAzijn, H., Tirry, I., Vingerhoets, J., de Béthune, M.-P., Kraus, G., Boven, K., Jochmans, D., Van Craenenbroeck, E., Picchio, G., & Rimsky, L. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00986-09 · Cited by 293 · cited 4×
“E138K + K101E + M184I (all) 4/37 (11) 3.”
InfluentialSelf-citationBacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2475-2484.2000 · Cited by 268 · cited 1×
“K101E 2(13) 6 (13) 8 (13) V106M 0 3 (19) 3 (11)”
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c990bf · Cited by 254 · cited 1×
“Subtype non-B 6/123 (5) 11/78 (14) 17/201 (8) 3/110 (3) 8/110 (7) 11/220 (5)”
Vingerhoets, J., Tambuyzer, L., Azijn, H., Hoogstoel, A., Nijs, S., Peeters, M., de Béthune, M.-P., De Smedt, G., Woodfall, B., & Picchio, G. (2010) · AIDS · doi:10.1097/qad.0b013e32833677ac · Cited by 185 · cited 1×
“B subtype‡ 13/245 (5) 42/240 (18) 55/485 (11) 13/220 (6) 15/242 (6) 28/462 (6)”
Self-citationPozniak, A., Morales-Ramirez, J. O., Katabira, E. T., Steyn, D., Lupo, S., Santoscoy, M., Grinsztejn, B. G. J., Ruxrungtham, K., Rimsky, L. T., Vanveggel, S., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32833032ed · Cited by 121 · cited 7×
“Subtype non-B 6/123 (5) 11/78 (14) 17/201 (8) 3/110 (3) 8/110 (7) 11/220 (5)”
InfluentialSelf-citationKulkarni, R., Babaoglu, K., Lansdon, E. B., Rimsky, L. T., Eygen, V. V., Picchio, G., Svarovskaia, E. S., Miller, M. D., & White, K. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823aca74 · Cited by 87
Self-citationTambuyzer, L., Nijs, S., Daems, B., Picchio, G., & Vingerhoets, J. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182237f74 · Cited by 77 · cited 1×
“V90I 1 (6) 4 (9) 5 (8) K101E 1 (8) 0 1 (4)”
Self-citationPotent Inhibition of Human Enterovirus 71 Replication by Type I Interferon Subtypes
Yi, L., He, Y., Chen, Y., Kung, H., & He, M. (2011) · Antiviral Therapy · doi:10.3851/imp1720 · Cited by 63
Asahchop, E. L., Oliveira, M., Wainberg, M. A., BRENNER, B. G., Moisi, D. D., Toni, T. D., & Tremblay, C. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01192-10 · Cited by 60
Cited by
2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Metadata
- Authors
- Rimsky, L., Vingerhoets, J., Van Eygen, V., Eron, J., Clotet, B., Hoogstoel, A., Boven, K., & Picchio, G.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2012-01-01
- Volume
- 59
- Issue
- 1
- Pages
- 39-46
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2084302660
- Cited by
- 173
- References
- 13
- FWCI
- 15.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.